This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

£4M earmarked to repay Keydata cash

  • Print
  • Comment

The Financial Services Compensation Scheme has set aside nearly £4m from its budget for next year to recover the cost of compensating Keydata investors.

Last week, the FSCS published its plan and budget for 2012/13.

The proposed budget for the scheme’s management expenses, which is separate to compensation costs, is £65.2m, an 11 per cent increase from its £59m budget last year.

Out of the total budget, £3.9m has been set aside for professional and legal expenses for pursuing recoveries, for example, from Keydata.

The scheme estimates that it will have paid 3,996 Keydata claims in 2011/12, and forecasts it will receive between 160 and 1,260 new Keydata claims over the next year.

In October, law firm Herbert Smith wrote to IFAs who sold Keydata products on behalf of the FSCS to begin the legal process of recouping money paid out to Keydata investors.

The FSCS says it expects to incur “substantial continuing legal costs in pursuing recoveries, in particular following the failure of Keydata”.

It adds: “We are claiming significant recoveries from both the Lifemark entity and claims against the adviser firms. However, we do not currently forecast receiving any such recoveries in 2012/13.”

Last April, the FSCS recouped £28m from Norwich & Peterborough Building Society which was paid in compensation to N&P Keydata customers.

  • Print
  • Comment

Daily Email Updates
If you enjoyed this article, sign up to receive the latest news and analysis from Money Marketing.

Money Marketing Awards 2015
Put your firm forward as the leading practitioner in your field. Adviser and Advertising categories are open to entries - Enter Now.

Have your sayEdit my profile/screen name

You must sign in to make a comment

Fund Data

Editor's Pick


How do you plan to vote at the general election?

Job of the week

Latest jobs

View all jobs

Most recent comments

View more comments